nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.12.2009 | Original Article

Local expression of interferon-alpha and interferon receptors in cervical intraepithelial neoplasia

verfasst von: Nelson R. Tirone, Bethanea C. Peghini, Ana Cristina M. Barcelos, Eddie F. C. Murta, Marcia A. Michelin

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The present study evaluated mRNA expression of interferon-alpha (IFN-α), IFN-α receptor subunits (IFNAR-1 and IFNAR-2) and an IFN-stimulated gene encoding the enzyme 2′,5′-oligoadenylate synthetase (2′5′OAS) in biopsies on patients with varying grades of cervical intraepithelial neoplasia (CIN I, II and III).

Methods

Uterine cervix biopsies were collected from women with CIN I, II and III (n = 28) and controls without CIN lesions or human papilloma virus (HPV) infection (n = 17). The presence of high and low-risk HPV DNA was determined using hybrid capture. The mRNA levels of IFNAR-1, IFNAR-2, IFN-α and 2′5′OAS were determined by RT-PCR with specific primers.

Results

The control group exhibited a greater frequency of IFNAR-1 expression (10/17; 58.3%) than the CIN samples (4/28; 14.2%) (P = 0.0018), while, the expression of IFNAR-2 was also greater in the control samples (11/17; 64.7%) than in the patients with lesions (2/28; 7.1%) (P = 0.0018). Importantly, simultaneous expression of both receptors was observed only in the control group (8/17; 47.0%) (P = 0.0001). Among the CIN samples, there was one case of low expression of mRNA of IFNAR-1 and IFNAR-2. IFN-α was present in 14.2% (4/28) of the CIN samples but was not expressed in the control group. mRNA 2′5′OAS were expressed in 28.5% (8/28) of the CIN samples and 11.7% (2/17) of the control samples (not statistically significant). Fifty percent (14/28) of the CIN samples were positive for HPV DNA.

Conclusions

Cervical biopsy samples from control women or those without neoplasia or HPV infection displayed higher IFN-α receptor expression than those with CIN, while simultaneous expression of both IFN-α receptor subunits was found only in the control group. There was no significant difference in mRNA expression of IFN-α and 2′5′OAS between the control and CIN groups. Then we concluded that the samples obtained from patients with CIN present low levels of the IFN-α receptor mRNA.

Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801PubMedCrossRef

Arany I, Goel A, Tyring SK (1995) Interferon response depends on viral transcription in human papillomavirus-containing lesions. Anticancer Res 15:2865–2869PubMed

Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (2008) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975–990CrossRef

Chieux V, Hober D, Chehadeh W, Wattr P (1999) Anti-viral proteins: from interferon alpha to its receptor. Ann Biol Clin 57(3):283–290

Cintorino M, Tripodi SA, Romagnoli R, Ietta F, Ricci MG, Paulesu L (2002) Interferons and their receptors in human papillomavirus lesions of the uterine cervix. Eur J Gynaecol Oncol 23:145–150PubMed

Damdinsuren B, Nagano H, Wada H, Noda T, Natsag J, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Monden M (2007) Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells. Hepatol Res 37:77–83PubMed

De Marco F, Manni V, Guaricci N, Muller A, Marcante ML (1999) Induction of apoptotic cell death by IFN beta on HPV-16 transformed human keratinocytes. Antiviral Res 42:109–120PubMedCrossRef

Diop G, Hirtzig T, Do H, Coulonges C, Vasilescu A, Labib T, Spadoni JL, Therwath A, Lathrop M, Matsuda F, Zagury JF (2006) Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother 60:569–577PubMedCrossRef

Doan T, Herd K, Street M, Bryson G, Fernando G, Lambert P, Tindle R (1999) Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J Virol 73:6166–6170PubMed

10.

Dondi E, Pattyn E, Lutfalla G, Ostade XV, Uzé G, Pellegrini S, Tavernier J (2001) Down-modulation of type i interferon responses by receptor cross-competition for a shared JAK kinase. J Biol Chem 276:47004–47012PubMedCrossRef

11.

El-Sherif AM, Seth R, Tighe PJ, Jenkins D (2001) Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol 195:179–185PubMedCrossRef

12.

Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, Sheehan K, Hilton DJ, Alexander WS, Hertzog PJ (2006) Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 7(1):33–39PubMedCrossRef

13.

Fontaine V, Van der Meijden E, Ter Schegget J (2001) Inhibition of human papillomavirus-16 long control region activity by interferon-gamma overcome by p300 overexpression. Mol Carcinog 31:27–36PubMedCrossRef

14.

Frodsham AJ, Zhang L, Dumpis U, Taib NA, Best S, Durham A, Hennig BJ, Hellier S, Knapp S, Wright M, Chiaramonte M, Bell JI, Graves M, Whittle HC, Thomas HC, Thursz MR, Hill AV (2006) Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci USA 103:9148–9153PubMedCrossRef

15.

Goodbourn S, Didcock L, Randall RE (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81:2341–2364PubMed

16.

Hovanessian AG, Justesen J (2007) The human 2′-5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie 89:779–788PubMedCrossRef

17.

Isaacs A, Lindenmann J (1957) Virus interference I. The interferon. Proc R Soc Lond B Biol Sci 147:258–267PubMedCrossRef

18.

Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216PubMedCrossRef

19.

Khan MA, Tolleson WH, Gangemi JD, Pirisi L (1993) Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons. J Virol 67:3396–3403PubMed

20.

Koromilas AE, Li S, Matlashewski G (2001) Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 12:157–170PubMedCrossRef

21.

Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, Pellegrini S, Matlashewski GJ, Koromilas AE (1999) The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 18:5727–5737PubMedCrossRef

22.

Matsumoto K, Okano J, Murawaki Y (2005) Differential effects of interferon alpha-2b and beta on the signaling on pathways in human liver cancer cells. J Gastroenterol 40:722–732PubMedCrossRef

23.

Michelin MA, Murta EFC (2007) Potential therapeutic vaccine strategies and relevance of immune system in uterine cervical cancer. Eur J Gynaecol Oncol 29:10–18

24.

Muñoz N, Bosch FX DE, Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527PubMedCrossRef

25.

Murta EFC (1998) Influência da idade materna, do período gestacional e do número de gestações na infecção pelo papilomavírus humano. Rev Bras Ginecol Obstet 20(1):33–35CrossRef

26.

Nawa A, Nishiyama Y, Yamamoto N, Maeno K, Goto S, Tomoda Y (1990) Selective suppression of human papilloma virus type 18 mRNA level in HeLa cells by interferon. Biochem Biophys Res Commun 170:793–799PubMedCrossRef

27.

Novick D, Cohen B, Rubinstein M (1994) The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77:391–400PubMedCrossRef

28.

Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M (2005) Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93:557–564PubMedCrossRef

29.

Pannetier D, Faure C, Georges-Courbot MC, Deubel V, Baize S (2004) Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. J Virol 78(19):10516–10524PubMedCrossRef

30.

Pao CC, Lin CY, Yao DS, Tseng CJ (1995) Differential expression of cytokine genes in cervical cancer tissues. Biochem Biophys Res Commun 214:1146–1151PubMedCrossRef

31.

Perea SE, Lopez-Ocejo O, Garcia-Milian R, Arana MJ (1995) Interferon-alpha elicits downregulation of human papillomavirus 18 mRNA in HeLa cells by selective repression of endogenous viral transcription. J Interferon Cytokine Res 15:495–501PubMedCrossRef

32.

Platanias LC, Uddin S, Colamonici OR (1994) Tyrosine phosphorylation of the D and E subunits of the type I interferon receptor. J Biol Chem 269:17761–17764PubMed

33.

Richart RM, Shingleton HM, Wiener J, Spiro D (1968) Human cervical intraepithelial neoplasia: fine structure of dysplasia and carcinoma in situ. Cancer Res 28(4):695–706PubMed

34.

Ronco LV, Karpova AY, Vidal M, Howley PM (1998) Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 12:2061–2072PubMedCrossRef

35.

Saito T, Ji G, Shinzawa H, Okumoto K, Hattori E, Adachi T, Takeda T, Sugahara K, Ito JI, Watanabe H, Saito K, Togashi H, Ishii K, Matsuura T, Inageda K, Muramatsu M, Kawata S (2004) Genetic variations in humans associated with differences in the course of hepatitis C. Biochem Biophys Res Commun 30:335–341CrossRef

36.

Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14:778–809PubMedCrossRef

37.

Song SH, Lee JK, Lee NW, Saw HS, Kang JS, Lee KW (2008) Interfeon-γ: a possible prognostic marker for clearance of high-risk human papilomavirus (HPV). Gynecol Oncol 108(3):543–548PubMedCrossRef

38.

Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264PubMedCrossRef

39.

Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR (1992) Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 23(2):117–128PubMedCrossRef

40.

Uthaisangsook S, Day NK, Bahna SL, Good RA, Haraguchi S (2002) Innate immunity and its role against infections. Ann Allergy Asthma Immunol 88:253–264PubMedCrossRef

41.

Uze G, Lutfalla G, Bandu MT, Proudhon D, Moogensen KE (1992) Behaviour of a cloned murine interferon alpha/beta receptor expressed in homospecific or heterospecific background. Proc Natl Acad Sci USA 89:4774–4778PubMedCrossRef

42.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19PubMedCrossRef

43.

Woodworth CD, Lichti U, Simpson S, Evans CH, Di Paolo JA (1992) Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res 52:456–463PubMed

44.

Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5(7):730–737PubMedCrossRef

45.

Zimmerer JM, Lesinski GB, Kondadasula SV, Karpa VI, Lehman A, Raychaudhury A, Becknell B, Carson WE (2007) IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol 178:4832–4845PubMed

Titel: Local expression of interferon-alpha and interferon receptors in cervical intraepithelial neoplasia
verfasst von: Nelson R. Tirone
Bethanea C. Peghini
Ana Cristina M. Barcelos
Eddie F. C. Murta
Marcia A. Michelin
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0707-6

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Local expression of interferon-alpha and interferon receptors in cervical intraepithelial neoplasia